Anifrolumab inhibits type 1 interferon from increasing immune system activity

Anifrolumab FDA approval to treat systemic lupus [Saphnelo]

Anifrolumab FDA Approval to Treat Systemic Lupus Erythematosus (SLE)

AstraZeneca announced its anifrolumab FDA approval on 8/2/2021. In this blog, learn how anifrolumab works, how it is given, and its potential side effects. If you are a patient with lupus that is not in remission, this brings you hope for a potentially better treatment, read more below. If you are a healthcare provider searching for detailed information on the indications, dosing, and precautions, read more below.

The anifrolumab brand name is Saphnelo

History was made when the U.S. Food and Drug Administration (FDA) gave final approval to use anifrolumab (Saphnelo) as a safe and effective treatment for SLE. Note that anifrolumab is the generic drug name, and Saphnelo is the trade (brand) name. It is produced by AstraZeneca.

Read more